Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.

Progress in neuro-psychopharmacology & biological psychiatry·2019
Same author

Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion.

Journal of affective disorders·2019
Same author

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies.

Neuropsychiatric disease and treatment·2018
Same author

Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date.

Expert opinion on investigational drugs·2018
Same author

The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.

Journal of affective disorders·2018
Same author

A pilot case-control study on the association between N-acetyl derivatives in serum and first-episode schizophrenia.

Psychiatry research·2018

Related Experiment Video

Updated: Jun 7, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

When should you move beyond first-line therapy for depression?

Roger S McIntyre1

  • 1Department of Psychiatry, University of Toronto, Toronto, ON, Canada. roger.mcintyre@uhn.on.ca

The Journal of Clinical Psychiatry
|October 28, 2010
PubMed
Summary

Achieving remission in major depressive disorder (MDD) with first-line treatment is challenging, with only about 30% of patients responding. Early symptom improvement at two weeks can predict later remission, but reliable biomarkers for treatment response remain elusive.

More Related Videos

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Related Experiment Videos

Last Updated: Jun 7, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major Depressive Disorder (MDD) treatment efficacy with first-line pharmacotherapy is limited, with only ~30% achieving remission.
  • Optimal therapeutic effects from antidepressant pharmacotherapy typically manifest within 4-6 weeks, potentially longer with psychotherapy.
  • Early symptomatic improvement (≥20% on HAM-D17 at 2 weeks) predicts remission, while lack of improvement is a strong negative predictor.

Purpose of the Study:

  • To review the current understanding of treatment timelines and predictors for major depressive disorder (MDD).
  • To explore the potential of emerging biomarkers, such as quantitative electroencephalography (QEEG), in predicting antidepressant response.
  • To address the clinical challenge of determining when to modify treatment for patients with MDD.

Main Methods:

  • Literature review of studies on pharmacotherapy and psychotherapy for MDD.
  • Analysis of data regarding early symptomatic improvement as a predictor of remission.
  • Examination of emerging electrophysiological measures for predicting treatment outcomes.

Main Results:

  • No current antidepressant or class demonstrates a faster onset of action.
  • Early improvement (2 weeks) predicts remission (6-8 weeks), and lack of improvement is a robust negative predictor.
  • Frontal quantitative electroencephalography (QEEG) shows potential for identifying remitters within 1-2 weeks.

Conclusions:

  • Predicting and optimizing antidepressant response in MDD remains a significant clinical challenge.
  • While early symptomatic response is informative, reliable biomarkers are still needed.
  • Emerging electrophysiological measures like QEEG may offer future tools for personalized treatment selection in MDD.